Skip to content

Clinical study of Danzhi Qing'e Fang and Erzhi Fang for menopausal symptoms

Danzhi Qing'e Fang and Erzhi Fang for menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001371
Enrollment
Unknown
Registered
2011-06-08
Start date
2011-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

menopausal symptoms

Interventions

A Combined formula Group:Jiawei Qing'e Fang +Erzhi Wan
A Jiawei Qing’e Fang Group:Jiawei Qing’e Fang+Erzhi Wan Placebo
A Erzhi Wan Group:Jiawei Qing'e Fang Placebo+Erzhi Wan
A Placebo Group:Jiawei Qing'e Fang Placebo+Erzhi Wan Placebo
B Jiawei Qing’e Fang Group:Jiawei Qing'e Fang+Erzhi Wan Placebo
B Erzhi Wan Group:Jiawei Qing'e Fang Placebo+Erzhi Wan
B Combined formula Group:Jiawei Qing'e Fang +Erzhi Wan
B Placebo Group:Jiawei Qing'e Fang Placebo+Erzhi Wan Placebo

Sponsors

Tianjin Univesity of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Period A (perimenopausal period) 1. Female aged 40 to 60 years old in their perimenopausal period(marked by irregular cycles and menopausal symptoms); 2. The subjects meet diagnostic criteria of menopausal symptoms; 3. FSH>=10 IU/L; 4. At least 14 hot flushes per week within the past four weeks; 5. Sign the informed consent form. Period B (early postmenopausal period): 1. Female aged 40 to 60 years old in their early postmenopausal period 1 to 5 years; 2. The subjects meet diagnostic criteria of menopausal symptoms; 3. FSH>=20 IU/L; 4. At least 14 hot flushes per week within the past four weeks; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Mammary hyperplasia, metropolypus, abnormal vaginal bleeding, myoma of uterus larger than 2.0*2.0cm; 2. Surgical menopause; 3. Irritable physique or hypersensitivity to the investigational drugs; 4. Patients with diseases as follows: Malignant tumor; hyperthyroidism, hypothyroidism, uncontrolled diabetes; Obesity (body mass index greater than 30); neurasthenia, psychiatric disorders, migraine headache; organic cardio-cerebral vascular diseases, hypertension, thrombotic diseases; gastrointestinal diseases affecting drug absorption; hematopoietic system diseases, autoimmune system diseases. Fungal or bacterial vaginal infections; 5. Abnormal hepatic function or abnormal renal function; 6. With history of smoking or alcohol abuse; 7. Use the same treatment of traditional Chinese medicine in the previous 4 weeks; Use Estrogen or estrogen/progesterone drugs through vaginal or percutaneous or Po in the passed 8 weeks; Take progesterone implants or a separate injection of estrogen in the passed 3 months; Take estrogen pills or progesterone injection in the previous 6 months.

Design outcomes

Primary

MeasureTime frame
Menopause-specific quality-of-life (MENQOL);

Secondary

MeasureTime frame
FSH, E2, Testosterone;Hot flush frequency and severity;Serum lipids (total cholesterol, HDL and LDL chole;

Countries

China

Contacts

Public ContactXiumei GAO
gaoxiumei@tjutcm.edu.cn+86 13602020716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026